GlassScriptPhysician profile
Venkat S Ramanan
NPI 1659302818
$3,961.43
in general payments reported to CMS, 2019-2025
34 companies · $14.81 in 2025
The $14.81 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $507 · 2021: $1,015 · 2022: $1,141 · 2023: $101 · 2025: $14.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.54 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $574.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $480.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $263.81 | 2019-2022 | |
| Pfizer INC. | $203.90 | 2019-2022 | |
| Novo Nordisk INC | $193.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.68 | 2019-2022 | |
| Lilly USA, LLC | $143.93 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $131.32 | 2019-2022 | |
| Allergan, INC. | $98.03 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.42 | 2019-2022 | |
| Horizon Therapeutics Plc | $91.90 | 2019-2021 | |
| Esperion Therapeutics, INC. | $85.94 | 2020-2022 | |
| Sanofi Pasteur INC. | $85.48 | 2019-2020 | |
| Amgen INC. | $73.33 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $63.49 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $63.36 | 2019-2022 | |
| Abbott Laboratories | $61.08 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $58.93 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.58 | 2022 | |
| Amarin Pharma, INC. | $50.36 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $49.02 | 2019-2021 | |
| Astellas Pharma US INC | $41.72 | 2019-2023 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $38.35 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $29.30 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.72 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $25.65 | 2019 | |
| Sumitomo Pharma America, INC. | $22.29 | 2023 | Gemtesa |
| Jazz Pharmaceuticals INC. | $17.70 | 2020 | |
| Lundbeck LLC | $16.41 | 2021 | |
| Boston Scientific Corporation | $14.81 | 2025 | General - Pain Management |
| Biohaven Pharmaceuticals, INC. | $12.21 | 2021 | |
| Eisai INC. | $12.14 | 2021 | |
| Upsher-Smith Laboratories LLC | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkat Ramanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.